Xu, S. ., Zheng, B. ., Su, B. ., Finkelstein, S. N., Welsch, R. ., Ng, K. ., & Shahn, Z. . (2024). Can metformin prevent cancer relative to sulfonylureas? A target trial emulation accounting for competing risks and poor overlap via double/debiased machine learning estimators. Am J Epidemiol. http://doi.org/10.1093/aje/kwae217
metformin
Doran, W. ., Tunnicliffe, L. ., Muzambi, R. ., Rentsch, C. T., Bhaskaran, K. ., Smeeth, L. ., … Warren-Gash, C. . (2024). Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records. BMJ Open Diabetes Res Care, 12. http://doi.org/10.1136/bmjdrc-2023-003548
Pollock, C. ., Sanchez, J. J. G., Carrero, J. J., Kumar, S. ., Pecoits-Filho, R. ., Lam, C. S. P., … Wheeler, D. C. (2023). Glucose-lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classification. Diabet Med, e15200. http://doi.org/10.1111/dme.15200
Zheng, B. ., Su, B. ., Ahmadi-Abhari, S. ., Kapogiannis, D. ., Tzoulaki, I. ., Riboli, E. ., & Middleton, L. . (2023). Dementia risk in patients with type 2 diabetes: Comparing metformin with no pharmacological treatment. Alzheimers Dement. http://doi.org/10.1002/alz.13349